The company's chief operating officer says that for small biotech developing drugs for mental illnesses and substance abuse, "they are probably better off partnering with us." Ever since Alkermes ...
El 19.12.2024, Alkermes plc (NASDAQ:ALKS), una empresa farmacéutica con una capitalización bursátil de 4.850 millones de dólares, anunció el prepago y finalización de un importante acuerdo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback